Announcements Trials

Browse Landscape

Phase

Phase 2 2 Phase 1/2 2 Phase 1 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 3 Unresectable or Metastatic Solid Tumors 1 Solid Tumors 1 Solid Tumor 1 Ovarian Neoplasms 1 Neoplasms 1 Hematologic Neoplasms 1 Glioblastoma 1 Fallopian Tube Neoplasms 1

Interventions

pembrolizumab 82 Paclitaxel 71 Gemcitabine 66 Carboplatin 61 Cisplatin 46 Docetaxel 44 Bevacizumab 41 Nivolumab 33 Irinotecan 31 Fluorouracil 29 Pemetrexed 28 Cyclophosphamide 26 Cetuximab 26 Capecitabine 26 Erlotinib Hydrochloride 22 venetoclax 21 trametinib 21 Leucovorin 20 Sorafenib 17 Albumin-Bound Paclitaxel 17 Afatinib 17 130-nm albumin-bound paclitaxel 17 Topotecan 16 Radiotherapy 16 Oxaliplatin 16 fludarabine 15 regorafenib 14 budigalimab 14 atezolizumab 14 Ipilimumab 14

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1 × Neoplasms × epacadostat × Clear all

NCT02862457 2022-08-19

MK-3475-434

Merck Sharp & Dohme LLC

Phase 1 Completed

34 enrolled 25 charts

Carcinoma, Non-Small-Cell Lung, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡